MedElevator Войти в исследования
← Поиск публикаций

DOI 10.23736/s2724-5985.25.04010-0

Медицинская библиотека · Minerva gastroenterology · 2025

Mirikizumab effectiveness in a pregnant woman with acute severe ulcerative colitis: a case report.

Murgiano Marco, Del Gaudio Angelo, Puca Pierluigi, Parello Simone, Calvez Valentin, Buongiorno Silvia, Laterza Lucrezia, Lopetuso Loris R, Gasbarrini Antonio, Ghi Tullio, Scaldaferri Franco

СтатьяКлинический случайПеревод в очереди

Аннотация

Acute severe ulcerative colitis is a potentially life-threatening condition that requires hospitalization with early and aggressive intervention to prevent complications. Mirikizumab (an anti-IL-23 monoclonal antibody) is recommended for the treatment of adult patients with moderate-to-severe ulcerative colitis. Currently, there is lack of evidence supporting its use in acute severe colitis, and no evidence has been produced on the use of this medication in pregnant women. A 30-year-old pregnant woman, with a 4-year history of corticosteroid-refractory pancolitis, who had failure to respond to multiple biological therapies, including infliximab, adalimumab, and vedolizumab, presented with acute severe ulcerative colitis and suspected threatened preterm rupture of membranes at 18 weeks' gestation. After administering five days of intravenous corticosteroids, the patient showed an unfavorable clinical and endoscopic response. Given the corticosteroid-refractory ASUC and the significant obstetric and neonatal risks associated with colectomy, Mirikizumab was initiated as a rescue therapy. Remarkably, within one day of receiving the first dose, the patient exhibited significant clinical improvement. One month after Mirikizumab initiation, the patient maintained clinical remission with improved markers. At 35 weeks and 4 days of gestation, the patient underwent an urgent cesarean section, delivering a preterm female infant. This is the first reported case regarding the efficacy and safety of Mirikizumab as a rescue therapy in a pregnant woman with severe acute ulcerative colitis. Further research is needed to confirm its efficacy in ASUC and the safety of this drug during pregnancy.

Для цитирования: Murgiano Marco, Del Gaudio Angelo, Puca Pierluigi, Parello Simone, Calvez Valentin, Buongiorno Silvia, Laterza Lucrezia, Lopetuso Loris R, Gasbarrini Antonio, Ghi Tullio, Scaldaferri Franco. Mirikizumab effectiveness in a pregnant woman with acute severe ulcerative colitis: a case report.. Minerva gastroenterology. 2025. DOI: 10.23736/s2724-5985.25.04010-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.